One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)
Phase 1
Completed
- Conditions
- Plague
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2008-09-15
- Lead Sponsor
- PharmAthene UK Limited
- Target Recruit Count
- 123
- Registration Number
- NCT00246467
- Locations
- ๐บ๐ธ
Accelovance, Amarillo, Texas, United States
๐บ๐ธFlorida Medical Research Institute, Gainesville, Florida, United States
๐ฌ๐งSimbec Research Limited, Merthyr Tydfil, United Kingdom
Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed
Phase 2
Completed
- Conditions
- Bacillus Anthracis (Anthrax)
- Interventions
- Biological: rPA vaccine containing alhydrogelBiological: AVA
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-09-15
- Lead Sponsor
- PharmAthene UK Limited
- Target Recruit Count
- 226
- Registration Number
- NCT00170469
- Locations
- ๐บ๐ธ
Greater Huntsville Family Practice, PC, Huntsville, Alabama, United States
๐บ๐ธPharamTex Research, Inc., Amarillo, Texas, United States
๐บ๐ธMiami Research Associates, South Miami, Florida, United States
Phase II Study of Range and Schedule of rPA Doses
Phase 2
Completed
- Conditions
- Prevention of Bacillus Anthracis (Anthrax) Infection
- Interventions
- Biological: rPA vaccine containing alhydrogel
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-09-15
- Lead Sponsor
- PharmAthene UK Limited
- Target Recruit Count
- 415
- Registration Number
- NCT00170456
- Locations
- ๐ฌ๐ง
GDRU, Quintiles Ltd, London, United Kingdom
๐ฌ๐งSimbec Research Limited, Merthyr Tydfil, United Kingdom
ยฉ Copyright 2025. All Rights Reserved by MedPath